Described herein is a bioinformatic method for determining the presence of viral contamination in a sample and if such viral contamination is present the identification of the type(s) of contamination. The method uses high throughput sequencing techniques on DNA and/or RNA present in a sample. The methods described herein facilitate in-process control and r processing for release of batches, cell banks, bulk harvest and raw materials.
The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the combined use of a PD-1 inhibitor, a TGF? inhibitor, and an adenosine inhibitor to treat cancer.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
3.
METHOD FOR GLYCOSYLATION PROFILING TO DESCRIBE FUNCTIONAL CHARACTERISTICS OF A BIOLOGIC MOLECULE
The glycosylation profile of a biologic molecule describes important aspects of such biologic molecule. The characterization of the glycosylation profile of a biologic molecule is an important part of the critical quality attributes in the manufacturing and analytical processes for biologic molecules. As such described herein are methods to determine and characterize the glycosylation profile of a biologic molecule. In particular, the method uses one or more indices to describe the glycosylation profile as a finger-print of such biologic molecule.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C12P 21/00 - Préparation de peptides ou de protéines
4.
IMPROVED TREATMENT METHODS USING DMDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES, AND BIOMARKER FOR PREDICTING AND/OR OPTIMISING SAID TREATMENT METHODS
The invention pertains to improved treatment methods using DMDS, in particular cladribine, for the treatment of autoimmune diseases, in particular multiple sclerosis, and biomarkers, in particular immune cell subtypes, for predicting and/or optimising said treatment methods. The methods described rely on the use of immune cell subtypes, in particular T cells, B cells, NK cells subtypes and their ratios as present in blood samples from the patients for predicting and/or optimising the use of cladribine in the treatment of multiple sclerosis.
G01N 33/564 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
The invention relates to the field of protein purification processes involving several chromatography steps. The invention pertains to a method for purifying a protein, preferably an antibody or fragment thereof or a protein containing said fragment, from a complex solution, wherein said method comprises at least two chromatography steps which are performed using buffers comprising or consisting of the same chemical compounds. The invention is particularly useful for large scale production and purification of recombinant proteins.
The present disclosure relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the combined use of a PD-1 inhibitor, a TGF-beta inhibitor, and a MCT4 inhibitor to treat cancer.
C07D 213/71 - Atomes de soufre auxquels est lié un second hétéro-atome
C07K 14/71 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des régulateurs de croissance
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present disclosure relates to combination therapies useful for the treatment of cancer. In particular, the disclosure relates to the combined use of a PD-1 inhibitor, a TGFbeta inhibitor, and a PARP inhibitor to treat cancer.
C07K 14/71 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des régulateurs de croissance
A61K 31/454 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pimozide, dompéridone
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
8.
NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
The present invention encompasses NHE-1 inhibitors for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.
A61K 31/166 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p.ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 31/402 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil substitués par un groupe aryle en position 1, p.ex. pirétanide
Described herein is dispensing cup for use with medicaments, which dispensing cup in use allows for the patient to (self) administer an oral medicament (tablet or capsule) without the need to come into direct (skin) contact with such medicament.
The present disclosure relates to methods related to the treatment of IgA nephropathy. More specifically, the present disclosure relates to methods for treating a patient having IgA nephropathy (IgAN), to methods for reducing the serum Gd-IgAl level in a patient having IgA nephropathy (IgAN), to methods for reducing the proteinuria in a patient having IgA nephropathy, to methods for reducing the serum Gd-IgAl level and the proteinuria in a patient having IgA nephropathy, and further related disclosure. Agents used in these methods are transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI)- immunoglobulin (Ig) fusion molecules (TACl-Ig/TACI-Fc fusion molecules) such as atacicept.
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61P 3/12 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase des électrolytes
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
11.
COMBINATION TREATMENT FOR CANCER BASED UPON AN ICOS ANTIBODY AND A PD-L1 ANTIBODY TGF-BETA-RECEPTOR FUSION PROTEIN
The invention relates to a method of treating cancer, involving the combination of an ICOS binding protein, a PD-1 inhibitor and a TGF-? inhibitor. In particular, the invention relates to an ICOS binding protein (e.g. an anti-ICOS antibody) and a fusion protein targeting human protein Programmed Death Ligand 1 (PD-L1) or Programmed Cell Death Protein 1 (PD-1), and Transforming Growth Factor ? (TGF-?) (e.g. an anti-PD-(L)1(IgG):TGF?R fusion protein, comprising, for example, an anti-PD-L1 antibody and a TGF?RII or a fragment capable of binding to TGF-?).
C07K 14/71 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des régulateurs de croissance
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
12.
CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES
The invention described herein relates to an improved method for analytical capillary gel electrophoresis (CGE) for complex biologic molecules. The methods for the improved CGE include steps for the partial reduction of the biologic analyte molecule for use as calibration standard and use such partially reduced calibration sample to obtain an improved calibration curve for CGE to be used with biologic analyte molecules.
Transdermal drug delivery devices are described herein such as a microneedle array patch, to be placed on the skin for transdermal delivery of a medicament. The transdermal drug delivery device for delivery of a bioactive agent through mammalian skin comprises an array of microneedles and a means to actuate the microneedles, wherein the actuation means actuates the microneedles separately.
A61M 37/00 - Autres appareils pour introduire des agents dans le corps; Percutanisation, c. à d. introduction de médicaments dans le corps par diffusion à travers la peau
The present invention relates to a pharmaceutical composition, particularly a pharmaceutical composition comprising an IgG:TGF?RII (such as an anti-PD-L1:TGF?-inhibiting) fusion protein. The present invention also relates inter alia to a method of manufacturing the composition, to a kit including the composition, to a package including the composition, to a method of manufacturing the package, and to methods of treatment using the composition and/or package, especially cancer treatments.
A61K 47/14 - Esters d’acides carboxyliques, p.ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/18 - Amines; Amides; Urées; Composés d’ammonium quaternaire; Acides aminés; Oligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the combined use of a PD-1 inhibitor, a TGF? inhibitor, an ATM inhibitor and radiation to treat cancer.
A61K 31/4745 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. phénanthrolines
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
Described herein is a home stock management system (1) for packaged items comprising a stationary data collection module (10) configured to wirelessly collect data from one or more packaged items (11) and to transmit the collected data to a processing module (12) wherein the packaged item(s) (11) include(s) a wireless tag (15), a processing module (12) for receiving, storing and processing the collected data from the collection module (10), and a notification means (13), wherein, the data collection module (10) is configured to collect data from the one or more packaged items (11) present in the home without user intervention. The processing module (12) is configured to process the collected data to determine status information and the notification means (13) is configured to communicate to one or more authorized users the status information. The home stock management system (1) can be used for the monitoring of consumable packaged items in the house or for monitoring and managing the stock and use of medication in a patient home or residence.
17.
COMMUNICATION APPARATUS FOR USE WITH ELECTRONIC COMMUNICATION ELEMENT, ELECTRONIC COMMUNICATION ELEMENT AND USES THEREOF
There is described a communication system (1) comprising a central unit (3) and a communication element (20). The central unit (3) comprises at least one RF antenna (4), a transmitter (6) configured to transmit a RF signal and a receiver (8) configured to receive a backscattered RF signal. The communication element (20) comprises a RF antenna (22) and a modulator (23) configured to backscatter the RF signal. The communication element (20) comprises a means for modulating the backscattered RF signal into a spread spectrum backscattered RF signal, and a means for supplying power.
Injection device (2) comprising a housing (3), a syringe cradle (12) for removably receiving a syringe (1) having a needle (7), a container (10) with a flange (11), a plunger (9) and a removable needle cap (8) in the housing, and a system for performing automated injection comprising: - a cap actuation mechanism (4) for gripping, storing and retrieving the needle cap, - a syringe actuation mechanism (5) for moving the syringe in an injection direction (Id) from a position where the needle is inside the housing to an injection position where the needle projects out of a needle port of the housing on a skin contact face of the housing, and - a plunger actuation mechanism (6) for advancing the plunger for administration of the liquid drug.
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/145 - Perfusion sous pression, p.ex. utilisant des pompes utilisant des réservoirs sous pression, p.ex. au moyen de pistons
A61M 5/28 - Ampoules ou cartouches-seringues, c. à d. ampoules ou cartouches munies d'une aiguille
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
Provides herein is a method for identifying the specific cell lineage of cells in culture comprising the steps of determining from the nucleic acid molecules isolated from said recombinant cells in culture the presence of polymorphisms or SNPs at at least 5 different positions within at least five genes 5 contained in said nucleic acid molecules, obtaining a genetic profile from the determination of the previous step, and identiyfing the cell lineage of said cells in culture from said genetic profile, and wherein the recombinant cells produce a recombinant protein.
C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes
20.
METHOD FOR CONTROLLING THE AFUCOSYLATION LEVEL OF A GLYCOPROTEIN COMPOSITION
The present invention relates to a method for controlling the afucosylation level of a glycoprotein composition. The method comprises the control of the afucosylation level by selecting the appropriate temperature and/or pH. The invention also relates to glycoprotein compositions produced according to the method of the invention.
C12P 21/00 - Préparation de peptides ou de protéines
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
21.
METHODS FOR MODULATING PROTEIN MANNOSYLATION PROFILES USING MADURAMYCIN, NARASIN, OR SALINOMYCIN
The present invention relates to methods and compositions for modulating mannosylation profile of recombinant proteins expressed by mammalian host cells during the cell culture process, using a polyether ionophore.
The present invention relates to a method for purifying proteins, such as Fc fusion proteins or antibodies, from a sample comprising said proteins and impurities, through the use of a three- chromatographic columns procedure, including a chromatography on hydroxyapatite- and/or Fluorapatite-containing material. The invention is also concerned with pharmaceutical compositions comprising the purified proteins obtainable by the process of the invention.
Information about a drug-containing vessel is determined by capturing image data of the curved surface of a cylindrical portion of a drug-containing vessel. The image data is unfurled from around the curved surface, binarised, and a template matching algorithm employed to determine that the label information comprises candidate information about the vessel and/or the drug.
A system determines the location of a tip (106) of a hypodermic needle (104) by moving a needle along a path (108), shining light from two sources onto respective portions of the path, and analysing signals received from the respective light sources that have been reflected by the needle.
A61M 5/42 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour insensibiliser la peau, pour soulever la peau en vue de faciliter la piqûre ou pour localiser le point du corps où la piqûre doit être effectuée
25.
METHODS FOR MODULATING PRODUCTION PROFILES OF RECOMBINANT PROTEINS
The present invention relates to methods and compositions for culturing a host cell expressing a recombinant protein in a cell culture medium supplemented with feeds comprising effective amounts of valeric acid, whereby viability of the cells and production of said protein are increased relative to cells grown with feeds comprising no valeric acid.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12P 1/00 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymes; Procédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes
26.
METHODS FOR MODULATING PROTEIN GALACTOSYLATION PROFILES OF RECOMBINANT PROTEINS USING PERACETYL GALACTOSE
The present invention relates to methods and compositions for modulating glycosylation profile, such as the galactosylation profile, of recombinant proteins expressed by mammalian host cells during the cell culture process by supplementing cell culture media with a peracetyl galactose.
The invention relates to a method for determining the clonality of a master cell bank (MCB) in which a transgene has been inserted. The method involves a combination of sequencing methodology and bioinformatic analysis, performed on multiple subclones originating from a common MCB, to establish a reliable set of reference transgene insertion regions in one reference subclone, and corresponding sets of comparative transgene insertion regions in one or more other subclones originating from the same MCB. Based on the degree of congruity between reference and comparative transgene insertion regions, the MCB is determined to be either monoclonal or polyclonal.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
28.
METHODS FOR MODULATING PRODUCTION PROFILES OF RECOMBINANT PROTEINS
The invention is in the field of cell culture. Particularly the invention relates to methods of culturing a host cell expressing a recombinant protein in a cell culture medium comprising an effective amount of 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) or supplemented with an effective amount of DIDS, whereby production of said protein is increased relative to cells grown without DIDS.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
The invention is in the field of cell culture. Particularly the invention relates to methods of culturing a host cell expressing a recombinant protein in a cell culture medium comprising an effective amount of a triazine dye or supplemented with an effective amount of a triazine dye, whereby production of said protein is increased relative to cells grown without said triazine dye or any other inducer.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
Disclosed are immunoassays for quantification of a high positively charged protein, such as FGF-18 protein, in a human synovial fluid sample. Selected methods involve pre- treating the sample with a hyaluronidase solution, diluting the sample with a buffer, immobilizing a biotinylated antibody against the protein to a column, and contacting the column with the pre-treated and diluted human synovial fluid sample, and further involving a fluorescent dye labelled antibody specific for the protein to determine a quantity of the protein present in the sample.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
The present invention relates to novel liquid protein formulations, particularly arginine-free liquid pharmaceutical compositions of etanercept. The invention employs particular combinations and classes of buffer systems, tonicifiers, and sugar stabilisers, optionally alongside polar ionisable amino acids (e.g. aspartic acid, glutamic acid, histidine, and lysine), to afford a viable and storable drug product.
A61K 47/18 - Amines; Amides; Urées; Composés d’ammonium quaternaire; Acides aminés; Oligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
32.
PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF
Disclosed are pyrazole compounds, for example compounds of the formula I: and pharmaceutically acceptable compositions thereof. The compounds and the compositions can be used for positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
C07D 491/052 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à six chaînons
A61K 31/4162 - 1,2-Diazoles condensés avec des systèmes hétérocycliques
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p.ex. inducteurs d'ovulation ou de spermatogénèse
The invention relates to the field of pharmaceutical formulations. More particularly it is directed to xyloglucan hydrogels comprising Fibroblast Growth Factor 18 (FGF-18) compound and to methods of producing such hydrogels. The hydrogels of the invention can be used, once formed in situ, for the treatment of cartilage disorders such as osteoarthritis or cartilage injury.
The invention relates to the field of pharmaceutical formulations. More particularly it is directed to homogeneous hydrogels comprising Fibroblast Growth Factor 18 (FGF-18) compound and to methods of producing such hydrogels. The hydrogels of the invention can be used, once formed in situ, for the treatment of cartilage disorders such as osteoarthritis or cartilage injury.
A medical device connection station comprising a body having a first portion of a docking interface to dock with a corresponding second portion of a docking interface of a medical device, a control unit controlling a medical device communication interface for communication with a docked medical device and controlling a server communication interface. The control unit is configured acquire medical data from a docked medical device via the medical device communication interface and is further configured to connect with and obtain a data session with the server system via the server communication interface, and to thereby transfer the medical data to the server system. The medical device connection station further comprises a lid connected to the body and movable between a first and second position, wherein in the first position the lid prevents first portion of the docking interface from docking with the second portion of the docking interface of the medical device, and wherein in the second position the first portion of the docking interface is operable to dock with the second portion of the docking interface. The medical device connection station comprises a lid movement sensing unit which is configured to sense movement of the lid between the first position and the second position and to thereby provide a signal to the control unit, the control unit configured to receive the signal to initiate the connection to the server system.
G16H 40/60 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux
H04W 12/02 - Protection de la confidentialité ou de l'anonymat, p.ex. protection des informations personnellement identifiables [PII]
H04W 84/12 - Réseaux locaux sans fil [WLAN Wireless Local Area Network]
A61M 99/00 - Matière non prévue dans les autres groupes de la présente sous-classe
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients
G16H 40/40 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion d’équipement ou de dispositifs médicaux, p.ex. pour planifier la maintenance ou les mises à jour
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
H04W 4/30 - Services spécialement adaptés à des environnements, à des situations ou à des fins spécifiques
G06F 1/16 - TRAITEMENT ÉLECTRIQUE DE DONNÉES NUMÉRIQUES - Détails non couverts par les groupes et - Détails ou dispositions de structure
H04L 9/06 - Dispositions pour les communications secrètes ou protégées; Protocoles réseaux de sécurité l'appareil de chiffrement utilisant des registres à décalage ou des mémoires pour le codage par blocs, p.ex. système DES
H04L 12/16 - Dispositions pour la fourniture de services particuliers aux abonnés
G16H 20/13 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients delivrés par des distributeurs
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
36.
A LIQUID FORMULATION OF A FUSION PROTEIN COMPRISING TNFR AND FC REGION
Disclosed is a liquid formulation comprising a TNFR-Fc fusion protein and a stabilizer, in which the fusion protein comprises TNFR (tumor necrosis factor receptor) or a fragment thereof and an immunoglobulin Fc region, and the stabilizer comprises one or more amino acids selected from the group consisting of proline and histidine, a buffer solution, and an isotonic agent containing sodium chloride (NaC1) and sucrose, and a preparation method of the liquid formulation. The liquid formulation according to the present invention provides excellent storage stability because long-term storage of TNFR-Fc fusion protein (etanercept) is possible and particular storage conditions are not needed. Since the liquid formulation of the present invention shows excellent storage stability even though the formulation is simple, it is more economical than other stabilizers or lyophilized formulations, and thus the formulation can be effectively applied for uses wherein treatment of TNFR-Fc fusion protein (etanercept) is beneficial.
The present invention relates to new serum-and protein-free culture media. These media are high performance culture media, which notably improve mammalian fed-batch cultures. The present invention also relates to methods for preparing and/or designing the medium, and methods of use thereof.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
38.
APPARATUS, METHOD, AND SYSTEM FOR IMAGE-BASED HUMAN EMBRYO CELL CLASSIFICATION
Apparatuses, methods, and systems for automated cell classification, embryo ranking, and/or embryo categorization are provided. In one embodiment, an apparatus includes a classification module configured to apply classifiers to images of one or more cells to determine, for each image, a classification probability associated with each classifier. Each classifier is associated with a distinct first number of cells, and is configured to determine the classification probability for each image based on cell features including one or more machine learned cell features. The classification probability indicates an estimated likelihood that the distinct first number of cells is shown in each image. Each of the images thereby has classification probabilities associated therewith.
C12Q 1/04 - Détermination de la présence ou du type de micro-organisme; Emploi de milieux sélectifs pour tester des antibiotiques ou des bactéricides; Compositions à cet effet contenant un indicateur chimique
C12N 5/073 - Cellules ou tissus embryonnaires; Cellules fœtales ou tissus fœtaux
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p.ex. par des compteurs de colonies
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
Apparatuses, methods, and systems for automated, non-invasive evaluation of cell activity are provided. In one embodiment, an apparatus includes a hypothesis selection module configured to select a hypothesis from a plurality of hypotheses characterizing one or more cells shown in an image. Each of the plurality of hypotheses includes an inferred characteristic of the one or more cells based on geometric features of the one or more cells shown in the image. The hypothesis selection module is implemented in at least one of a memory or a processing device.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
A61B 17/435 - Instruments ou procédés de gynécologie ou d'obstétrique pour la reproduction ou la fertilisation pour la transplantation d'embryons
The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 407/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
The injection device comprises: a static structure (2) comprising a first gear member (14), a dynamic structure (3) comprising a medicine container (11), means (6, 7, 8, 12) for pushing liquid medicine out of said medicine container (11) for its injection to a patient, and a second gear member (13) engaged with the first gear member (14), a drive member (4) for driving one (14) of the first and second gear members (13, 14) so as to cause the dynamic structure (3) to move relative to the static structure (2) along a predetermined direction (D) due to the engagement between the first and second gear members (13, 14), and clutch means (23, 25, 28) for maintaining engagement between the first and second gear members (13, 14) in normal condition of the injection device, and for allowing disengagement of the first and second gear members (13, 14) upon a shock received by the injection device along the predetermined direction (D).
A61M 5/24 - Seringues à ampoules, c. à d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p.ex. automatiques
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
An injection device for injecting liquid medicine to a patient comprises a medicine container (2) an end of which is connectable to a needle (3) and magnetic sensor means (21, 22) for sensing connection of the needle (3) to the medicine container (2).
A61K 31/4427 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
Methods, compositions and kits for determining the likelihood of reaching the blastocyst stage for one or more embryos or pluripotent cells are provided. These methods, compositions and kits find use in identifying embryos and oocytes in vitro that are most useful in treating infertility in humans.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12N 5/073 - Cellules ou tissus embryonnaires; Cellules fœtales ou tissus fœtaux
A61B 17/435 - Instruments ou procédés de gynécologie ou d'obstétrique pour la reproduction ou la fertilisation pour la transplantation d'embryons
C12Q 1/04 - Détermination de la présence ou du type de micro-organisme; Emploi de milieux sélectifs pour tester des antibiotiques ou des bactéricides; Compositions à cet effet contenant un indicateur chimique
The present invention provides compounds of Formula (I) as inhibitors of LMP7 for the treatment of autoimmune and inflammatory diseases. In formula (I), Rb and Rc are independently selected from one another from H or C1-C6-alkyl; whereby Rb and Rc may be linked to form a 5 or 6 membered-ring containing the oxygen atoms to which they are linked; Q denotes Ar, Het or cycloalkyl; R1 R2 independently from each other denotes H, ORa, Hal, C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; Y denotes CR 3R4, preferably CH2 or C(CH3)2; R 3, R4 independently of one another denote H or C1-C6-alkyl; L denotes L1 or L2 or alkyl; n is an integer selected from 0 to 3; L 1 is Q1-CO-M- wherein Q 1 is Ar or Het, preferably, phenyl, naphthyl or pyridine, optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; L2 is Q2-M- wherein Q 2 is a fused bicyclic system containing 1 nitrogen atom and 1 to 3 additional groups independently selected from O, S, N, or CO, and wherein at least one of the rings is aromatic whereby the fused bicyclic system is optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; or Q 2 is unsaturated or aromatic 5 membered-ring system containing 1 to 3 heteroatoms selected from N, O, S and CO, and optionally substituted with a phenyl ring or pyridine ring whereby phenyl ring and pyridine ring are optionally substituted with 1 to 4 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; M is a linear or branched alkylene having 1 to 5 carbon atoms wherein 1 or 2 H atoms may be replaced by OR a or a phenyl ring optionally substituted with 1 to 5 groups independently selected from Hal, ORa, and C1-C6-alkyl optionally substituted with 1 to 5 groups independently selected from OH, and Hal; or M denotes a cycloalkylene having 3 to 7 carbon atoms; or M denotes a thiazolidinyl group; R a is H or C1-C6-alkyl wherein 1 to 5 H atom may be independently replaced by OH or Hal; Ar denotes a 6 membered-aromatic carbocyclic ring optionally fused with another carbocyclic saturated, unsaturated or aromatic ring having 5 to 8 carbon atoms; Het denotes a 5- or 6-membered saturated, unsaturated or aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from N, N+O-, O, S, SO, and SO 2, and optionally fused with another saturated, unsaturated or aromatic ring having 5 to 8 atoms and optionally containing 1 to 3 heteroatoms selected from N, O, and S; Hal denotes CI, Br, I of F; preferably CI or F.
The invention relates to the field of pharmaceutical formulations More particularly it is directed to freeze-dried formulations of Fibroblast Growth Factor 18 (FGF-18) compound and to methods of producing such formulations The freeze-dried formulations according to the invention are stable upon storage for an appropriate period of time They can be used, after reconstitution, for the treatment of cartilage disorders such as osteoarthritis or cartilage injury
Apparatuses, methods, and systems for the automated imaging and evaluation of human embryos, oocytes, or pluripotent cells are described. An apparatus and method for automated dish detection and well occupancy determination are described. In addition, a multi-well culture dish and an illumination assembly for bimodal imaging are described. These inventions find use at least in identifying or in facilitating identification of embryos and oocytes in vitro that are most useful in treating infertility in humans.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
A61B 10/02 - Instruments pour prélever des échantillons cellulaires ou pour la biopsie
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif
50.
COMBINATION OF BLYS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE
The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, ocrelizumab, ofatumumab (HuMax- CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.
The invention relates to a process for reducing the concentration of free Fc- moieties in a fluid comprising an Fc-containing protein comprising a cation exchange chromatography step.
This invention concerns the treatment of cartilage disorder and osteoarthritis in particular. More specifically, it relates to the use of FGF-18 in treatment regimens and for the manufacture of a medicament for the treatment of patients having a cartilage disorder such as osteoarthritis, such as for example knee osteoarthritis or secondary hip osteoarthritis. Specifically provided is a preferred treatment scheme comprising once weekly administration of an FGF-18 compound per treatment cycle.
An injection device for injecting medication to a patient, comprising a surface (5) having a through hole (3) for passage of a needle, is characterised by further comprising a capacitive proximity sensor (12, 13, 30) for detecting proximity or contact of human skin to/with said surface (5).
H03K 17/955 - Commutateurs de proximité utilisant un détecteur capacitif
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
55.
PROCESS FOR THE PURIFICATION OF IL-18 BINDING PROTEIN
The invention relates to a process for the production of IL-18 binding protein (IL-18BP), and to a composition comprising IL-18BP characterized by a specific glycosylation pattern.
The medication delivery device is designed to receive a replaceable medication container (5) and to determine an adjusted medication dose AD for each medication container (5) received if the amount of medication contained in the medication container (5) is not a multiple of a prescribed dose D. The adjusted medication dose is the dose to be delivered instead of the prescribed dose at each use of the medication delivery device with the medication container (5) received. The adjusted dose is determined by selecting one of a first dose, that is higher than the prescribed dose, and of a second dose, that is lower than the prescribed dose, as a function of a variable B that cumulates the values nAD . (AD - D), where nAD is equal to INT (Cont / AD) and Cont is the amount of medication in the medication container received.
A61M 5/24 - Seringues à ampoules, c. à d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p.ex. automatiques
A61M 5/145 - Perfusion sous pression, p.ex. utilisant des pompes utilisant des réservoirs sous pression, p.ex. au moyen de pistons
A61M 5/315 - Pistons; Tiges de piston; Guidage, blocage, ou limitation des mouvements de la tige; Accessoires disposés sur la tige pour faciliter le dosage
The present invention aims to reduce waste from medication left in a container after delivery of the medication. A medication delivery device comprises a piston rod and an electric motor for driving said piston rod. There is provided a method comprising: bringing the piston rod into contact with a piston of the medication container from a known, retracted position; detecting the contact by monitoring the amperage of the electric motor; counting the number of revolutions of said electric motor to determine the distance covered by said piston rod from its retracted position to its contact with said piston, and thus the position of the piston in the medication container; and determining an initial amount of medication contained in the medication container from the piston position, wherein the initial amount of medication in the medication container is the amount of medication in the medication container before any delivery of the medication.
A61M 5/24 - Seringues à ampoules, c. à d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p.ex. automatiques
A61M 5/145 - Perfusion sous pression, p.ex. utilisant des pompes utilisant des réservoirs sous pression, p.ex. au moyen de pistons
A61M 5/315 - Pistons; Tiges de piston; Guidage, blocage, ou limitation des mouvements de la tige; Accessoires disposés sur la tige pour faciliter le dosage
The present invention is related to macrogol glyceride pharmaceutical formulations containing benzothiazole derivatives. In particular, the invention is related to benzothiazole stearoyl macrogol pharmaceutical formulations, method of preparation and use thereof.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
62.
HAND-HELD ELECTRONICALLY CONTROLLED INJECTION DEVICE FOR INJECTING LIQUID MEDICATIONS
There is described a hand-held, electronically controlled injection device (1) for injecting preset doses of liquid medications, having a housing (2) for receiving a cartridge (4) containing the liquid medication and having a contact surface (16) for contacting a patient's skin; and actuator means (41) for moving the cartridge (4) within the housing (2) to and from the contact surface (16).
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/24 - Seringues à ampoules, c. à d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p.ex. automatiques
63.
HAND-HELD ELECTRONICALLY CONTROLLED INJECTION DEVICE FOR INJECTING LIQUID MEDICATIONS
The medication delivery device comprises a housing, a door which, in its open position, permits insertion/removal of a medication container into/from the housing, a door opening mechanism for opening/closing the door, and a push member which can be moved axially from a retracted position, located outside the medication container, to enter the medication container and push liquid medication contained in the medication container out of the medication container to deliver it to a patient, and then returned to its retracted position. The medication delivery device also comprises a lock mechanism for locking a door opening button of the door opening mechanism, to prevent opening of the door, when the push member is inside the medication container and for unlocking the door opening button when the push member is in its retracted position.
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/24 - Seringues à ampoules, c. à d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p.ex. automatiques
64.
HAND-HELD ELECTRONICALLY CONTROLLED INJECTION DEVICE FOR INJECTING LIQUID MEDICATIONS
The medication injection device comprises a housing, a holder for receiving and holding in said housing a medication container an end of which is connectable to a needle, a controller, and a device, controlled by said controller, for pushing liquid medication contained in the medication container out of the medication container through said needle. The medication injection device also comprises a first sensor, connected to the controller, for detecting proper connection of the needle to the medication container.
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/24 - Seringues à ampoules, c. à d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p.ex. automatiques
65.
PROCESS FOR THE PURIFICATION OF IL-18 BINDING PROTEIN
The invention relates to a process for the purification of IL-18 binding protein (IL-18BP) from a fluid comprising hydrophobic charge-induction chromatography.
The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
brevets
